Olympus increases endoscopy sales, monitors supply chain issues

The Covid-19 pandemic challenges are easing up for Olympus, but the company still predicts uncertain supply chains, higher costs and trading challenges between the US and China. Still, endoscopy sales have gone well at the Japanese medtech giant.

Photo: Yuriko Nakao/Reuters/Ritzau Scanpix

Japanese Olympus has added 22 percent to its revenue in the first nine months of the financial year, as reported in the medtech company’s third quarter figures.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs